Cell's behaviours of like growth, motility, differentiation and apoptosis are regulated by signals received from their environment. These extracellular signaling molecules include neurotransmitters, hormones and growth factors which regulate the activation of intracellular signaling pathways leading to changes in gene expression and cell fate. Cholinergic system through muscarinic M1 and M3 receptors play an important role in the regulation of pancreatic b-cell proliferation and insulin secretion. Cholinergic activity was decreased in the brain regions-hypothalamus, brain stem, corpus striatum, cerebral cortex and cerebellum during pancreatic regeneration. Muscarinic M1 receptors were decreased at time of regeneration while M3 receptors showed an increase. Gene expression studies confirmed the mRNA level of M1 and M3 receptors. These changes in the muscarinic receptors regulate sympathetic activity and maintain glucose level. Pancreatic muscarinic M1 and M3 receptor activity were increased during proliferation indicating that both receptors are stimulatory to pancreatic b-cell division. Acetylcholine dose dependently increased EGF induced DNA synthesis in pancreatic islets in vitro which is inhibited by muscarinic antagonist atropine confirming the role of muscarinic receptors. Acetylcholine also stimulated glucose induced insulin secretion in vitro which is inhibited by muscarinic M1 and M3 receptor antagonists. Thus it is suggested that central muscarinic M1 and M3 receptor subtypes functional difference regulates sympathetic and parasym-pathetic systems which control the islet cell proliferation and glucose homeostasis. Hydroxymethylglutaryl-coenzyme reductase inhibitors (statins) are widely used clinically to reduce serum low density lipoprotein but little is known about their effects in the central nervous system. Sprague-Dawley rats were administered simvastatin or pravastatin (10 mg, p.o.) once daily for 4 weeks. Serum triglyceride levels were similarly reduced in the simvastatin-treated (45%) and pravastatin-treated (48%) groups. Serum cholesterol levels, however, remained unchanged in both groups. Simvastatin treatment increased the expression of eNOS, D1 and D2 receptors at both mRNA (2.1-fold, 1.6-fold and 2.2-fold, respectively) and protein (1.8-fold, 1.3-fold and 1.5-fold, respectively) levels in the frontal cortex, but not in the striatum. Similar changes were not observed in the frontal cortex of the pravastatin-treated rats. There were also no observable changes in the expression of nNOS and iNOS in simvastatin-treated rats. These results suggest that lipophilic statins can alter dopaminergic functions via a central mechanism. Thus, their use may have important implications in the brain reward and reinforcing circuits as well as in disease states associated with dopaminergic abnormality. It is tempting to suggest that the up-regulation eNOS and the two dopamine receptors may be linked in a cause-effect relationship after simvastatin treatment. Prostaglandin E 2 (PGE 2) is a well established hyper...